CD274 and neoplasm: Per the aforementioned study by Ferris et all, Nivolumab had a 24-month OS rate of 16.9% and demonstrated OS benefit across patients with tumor PD-L1 expression ≥1% (HR [95% CI] = 0.55 [0.39–0.78]) and <1% (HR [95% CI] = 0.73 [0.49–1.09]), and regardless of tumor HPV status.